Patents Assigned to Biogen Idec
  • Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
    Publication number: 20070073047
    Abstract: Nucleic acid sequences encoding genes that are overexpressed by human ovarian cancers are provided. These genes and the corresponding antigens are useful diagnostic and therapeutic targets. The invention provides cancer therapies that target these antigens, especially using monoclonal antibodies that target the Anat-2 antigen.
    Type: Application
    Filed: June 10, 2003
    Publication date: March 29, 2007
    Applicant: Biogen Idec MA Inc.
    Inventors: Hariharan Kandasamy, Mark Daniels, Karen McLachlan
  • Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof
    Publication number: 20070072175
    Abstract: This invention relates to a nucleotide array containing polynucleotide probes complementary to, or fragments of, Cynomolgus monkey genes, and the use of such a nucleotide array to characterize the biological effects, including the actions, targets, and toxicities, of therapeutic agents in primates, e.g., a human, a Cynomolgus monkey, or a Rhesus monkey, in particular a nucleotide array to be used in identifying the toxicities of therapeutic agents administered to a non-human primate, e.g., a Cynomolgus monkey or a Rhesus monkey.
    Type: Application
    Filed: May 15, 2006
    Publication date: March 29, 2007
    Applicant: Biogen Idec MA Inc.
    Inventors: Matthew Cooper, Deborah Kinch, Michael Rosenberg, S. Subramaniam, Suzanne Szak, Huo Li, Raj Bandaru, Maher Derbel
  • Cell adhesion inhibitors
    Patent number: 7196112
    Abstract: Cell adhesion inhibitors can interact with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. An inhibitor including a polyethylene glycol moiety can have advantageous pharmaceutical properties.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: March 27, 2007
    Assignee: Biogen Idec MA Inc.
    Inventors: Wen-Cherng Lee, R. Blake Pepinsky, Mark Cornebise, Daniel Scott, Russell C. Petter
  • Clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
    Patent number: 7195750
    Abstract: New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: March 27, 2007
    Assignee: Biogen IDEC Inc.
    Inventors: William Raestetter, Christine A. White
  • Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
    Publication number: 20070065429
    Abstract: The invention provides methods for treating diseases involving aberrant amyloid-? (A?) peptide deposition, including Alzheimer's Disease, by the administration of Nogo receptor antagonists.
    Type: Application
    Filed: April 16, 2004
    Publication date: March 22, 2007
    Applicants: Biogen Idec MA Inc., Yale University
    Inventors: Daniel Lee, Weiwei Li
  • Gamma-1 And Gamma-3 Anti-Human CD23 Monoclonal Antibodies And Use Thereof As Therapeutics
    Publication number: 20070065435
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: August 7, 2006
    Publication date: March 22, 2007
    Applicant: Biogen Idec MA Inc.
    Inventors: Mitchell Reff, William Kloetzer, Takehiko Nakamura
  • ANTI-CD80 ANTIBODY HAVING ADCC ACTIVITY FOR ADCC MEDIATED KILLING OF B CELL LYMPHOMA CELLS ALONE OR IN COMBINATION WITH OTHER THERAPIES
    Publication number: 20070065436
    Abstract: Methods for treating B cell malignancies, in particular B cell leukemia and lymphoma, using an anti-CD80 antibody alone or in combination with an anti-CD20 antibody or chemotherapy is provided. These methods result in a synergistic anti-tumor response.
    Type: Application
    Filed: August 14, 2006
    Publication date: March 22, 2007
    Applicant: Biogen Idec Inc.
    Inventors: Kandasamy Hariharan, Nabil Hanna
  • Gamma-1 And Gamma-3 Anti-Human CD23 Monoclonal Antibodies And Use Thereof As Therapeutics
    Publication number: 20070065434
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: August 7, 2006
    Publication date: March 22, 2007
    Applicant: Biogen Idec MA Inc.
    Inventors: Mitchell Reff, William Kloetzer, Takehiko Nakamura
  • CD80 specific antibodies
    Patent number: 7192585
    Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (GD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
    Type: Grant
    Filed: May 31, 2005
    Date of Patent: March 20, 2007
    Assignee: Biogen Idec Inc.
    Inventors: Darrell R. Anderson, Nabil Hanna, Peter Brams
  • Nogo receptor binding protein
    Publication number: 20070059793
    Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.
    Type: Application
    Filed: March 17, 2004
    Publication date: March 15, 2007
    Applicant: Biogen Idec Ma Inc.
    Inventors: Sha Mi, John McCoy, R. Pepinsky, Daniel Lee
  • Antibodies having altered effector function and methods for making the same
    Publication number: 20070048300
    Abstract: The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.
    Type: Application
    Filed: February 22, 2006
    Publication date: March 1, 2007
    Applicant: Biogen Idec MA Inc.
    Inventors: Frederick Taylor, Ellen Garber
  • Renal regulatory elements and methods of use thereof
    Patent number: 7179901
    Abstract: Disclosed are cis-acting regulatory elements from a KIM-1 gene. The elements can be used to direct the expression of operably linked sequences in renal tissue.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: February 20, 2007
    Assignees: Biogen Idec MA Inc., The General Hospital Corporation
    Inventors: Michele Sanicola-Nadel, Catherine Hession, Richard Tizard, Jr., Joseph Bonventre
  • Treatment for inflammatory bowel disease with a fibronectin polypeptide
    Patent number: 7176184
    Abstract: A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: February 13, 2007
    Assignee: Biogen Idec MA Inc.
    Inventors: Roy R. Lobb, Linda C. Burkly
  • Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
    Patent number: 7175847
    Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies, or B7.1-binding fragments thereof, may be used for the treatment of Crohn's disease.
    Type: Grant
    Filed: May 22, 2000
    Date of Patent: February 13, 2007
    Assignee: Biogen Idec Inc.
    Inventors: Darrell R. Anderson, Nabil Hanna, Peter Brams
  • Nogo receptor homologs
    Patent number: 7173118
    Abstract: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: February 6, 2007
    Assignees: Biogen Idec MA Inc., Yale University
    Inventors: Stephen M. Strittmatter, Richard L. Cate, Dinah W. Y. Sah
  • Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
    Patent number: 7169387
    Abstract: The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: January 30, 2007
    Assignee: Biogen Idec MA Inc.
    Inventor: Paul Rennert
  • Immunoregulatory Antibodies and Uses Thereof
    Publication number: 20070009519
    Abstract: A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.
    Type: Application
    Filed: July 21, 2006
    Publication date: January 11, 2007
    Applicant: Biogen Idec Inc.
    Inventors: Kandasamy Hariharan, Nabil Hanna
  • Methods for treating fibrotic conditions
    Publication number: 20070009518
    Abstract: The present invention is directed to methods for treating fibrosis conditions, such as liver, kidney and lung fibrosis, as well as fibrosis conditions of other tissues of the body. The methods of the invention comprise administering to a patient in need of such treatment a therapeutically effective amount of a B-cell antagonist. Exemplary B-cell antagonists that can be used in the practice of the methods of the invention include antibodies against B-cell surface antigens (e.g., antibodies against CD20), and BAFF antagonists.
    Type: Application
    Filed: May 18, 2006
    Publication date: January 11, 2007
    Applicant: Biogen Idec Inc.
    Inventors: Tatiana Novobrantseva, Shelia Violette, Victor Kotelianski, Alexander Ibraghimov
  • COMBINATION THERAPY FOR TREATMENT OF AUTOIMMUNE DISEASES USING B- CELL DEPLETING/IMMUNOREGULATORY ANTIBODY COMBINATION
    Publication number: 20070003544
    Abstract: The present invention concerns treatment of autoimmune diseases with the combination of an immunoregulatory antibody, e.g. an anti-B7.1 or anti-B7.2 or anti-CD40L antibody and at least one B cell depleting antibody, such as CD19, CD20, CD22, CD23, or CD37, wherein such antibodies may be administered separately, or in combination, and in either order, over prolonged periods of time.
    Type: Application
    Filed: August 14, 2006
    Publication date: January 4, 2007
    Applicant: Biogen Idec Inc.
    Inventor: Nabil Hanna
  • Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
    Patent number: 7157276
    Abstract: Methods for clarification of cell samples using centrifugation in combination with depth filtration.
    Type: Grant
    Filed: June 21, 2004
    Date of Patent: January 2, 2007
    Assignee: Biogen IDEC Inc.
    Inventor: Christine Y Pham